DEVICES AND METHODS FOR ENHANCED SKIN PERFORATION FOR CONTINUOUS GLUCOSE MONITORING

• US 20170188898A1
• Filed: 12/09/2016
• Published: 07/06/2017
• Est. Priority Date: 03/28/2006
• Status: Active Application

• Current Assignee: Arkal, Inc..
• Original Assignee: Arkal, Inc..
• Inventors: JINA, Arvind N., TAMADA, Janet, DESAI, Shashi, LEE, Jonathan
• Application Number:
  US15/374,677
• Publication Number:
  US 20170188898A1
• Time in Patent Office: Days
• CPC Class Codes: A61B 5/14503 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence
• CPC Class Codes: A61B 5/1451 for interstitial fluid
• CPC Class Codes: A61B 5/14514 using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/14865 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
• CPC Class Codes: A61B 5/742 using visual displays A61B5/339 takes precedence

Abstract

The efficacy of tissue piercing elements in the area of transdermal drug delivery is well-documented. Multiple studies have shown that enhancement of skin permeation via creation of microscopic pores in the stratum corneum can greatly improve the delivery rates of drugs. However, skin perforation with tissue piercing elements is not the only factor affecting the rate of drug transport. Other factors including such as the formulation of the drug and rate of closure of the micropores closure also need to be considered. Similarly micro tissue piercing elements have been used with less success by several workers for continuous glucose monitoring.

Claims

1. A method of in vivo monitoring of an individual'"'"'s interstitial fluid analyte concentration comprising:

creating plurality of micropores through a stratum corneum layer of an area of the individual'"'"'s skin, where the plurality of micropores forms a plurality of fluid paths having a distal end in fluid communication with interstitial fluid of the individual and a proximal end in fluid communication with a sensing zone located outside of the patient'"'"'s body, where the fluid paths comprise an interior space extending between the distal and proximal ends;

delivering a sensing fluid filling within the interior space of the fluid paths;

allowing at least one analyte to passively diffuse from the patient'"'"'s interstitial fluid through the fluid paths and into the sensing zone; and

sensing a concentration of the at least one analyte in a sensing fluid within the sensing zone using a sensor located at least partially in the sensing zone, wherein the sensing fluid formulation comprises a chelating agent and or biochemical inhibitors adapted to keep the micropores, created by the tissue piercing elements, open for extended period to maintain an un-interrupted analyte flux through the fluid paths and to mitigate a decrease over time of the analyte flux through the fluid paths.

3. The method of claim 1 wherein the chelating agent comprises a sufficient concentration of the agent to keep the skin micropores open to maintain a constant analyte flux through the fluid paths for one and or several days.

5. The method of claim 1 wherein the agent comprises citrate ions and the concentration of citrate ion ranges from 0.1 mM to 250 mM.

6. The method of claim 1 or 2 wherein the sensing fluid comprises a phosphate buffered saline solution.

7. The method of claim 1 or 2 wherein the analyte is glucose.

8. The method of claim 1 or 2 wherein the analyte is other than glucose for example cholesterol, electrolytes or proteins.

9. The method of claim 1 or 2 further comprising inserting tissue piercing elements through the stratum corneum layer using a simple insertion applicator.

18. The analyte monitor of claim 1 wherein the flexible electrochemical gel pad can be adapted and integrated into a simple easy to use wearable wellness monitor for making healthy lifestyle decisions

19. The analyte monitor of claim 1 wherein the flexible electrochemical gel pad can be adapted to be integrated into a wearable wellness monitor containing other sensing devices such to measure for example galvanic skin response, skin temperature, heart rate and motion

20. The method of claim 1 and 10 wherein the digital graphical feedback provided to the user is the sum total of all parameters.

21. The analyte monitor of claim 1 and 10 wherein the analyte monitor provides information regarding a general physiological condition of the patient.

22. The wearable wellness monitor of claim 1 and 10 wherein the analyte monitor is not used for the diagnosis of diabetes or any other medical disease.

23. The wearable wellness monitor of claim 1 and 10 wherein the wellness monitor is suitable for use by all individuals regardless of their health status.

2. A method of in vivo monitoring of an individual'"'"'s interstitial fluid analyte concentration comprising:

creating a plurality of micropores through a stratum corneum layer of an area of the individual'"'"'s skin, where the plurality of micropores define a plurality of fluid paths in communication with an interstitial fluid of the individual, a proximal end of the fluid paths being in fluid communication with a sensing zone located outside of the patient'"'"'s body; and

where the sensing zone comprises a flexible sensor laminated to a buffered gel allowing at least one analyte to passively diffuse from the patient'"'"'s interstitial fluid through the fluid paths and into the sensing zone wherein the sensing gel formulation comprises a chelating agent and or biochemical inhibitors adapted to keep the micropores, created by the tissue piercing elements, open for extended period to maintain an uninterrupted analyte flux through the fluid paths and to mitigate a decrease over time of the analyte flux through the fluid paths.

4. The method of claim 2 wherein the chelating agent in the gel formulation comprises a sufficient concentration of the agent to keep the skin micropores open to maintain a constant analyte flux through the fluid paths for one and or several days.

10. An analyte monitor comprising:

a plurality of fluid paths, each fluid path comprising a distal opening adapted to be disposed on one side of a stratum corneum layer of a user'"'"'s skin, a proximal opening adapted to be disposed on another side of the stratum corneum layer and an interior space extending between the distal and proximal openings;

a sensing zone in fluid communication with the proximal openings of the fluid paths; and

sensing fluid extending from the sensing zone into substantially the entire interior space of the fluid paths, wherein the sensing fluid comprises one or more chelating agent adapted to keep the micropores or microchannels open to maintain a constant analyte flux through the fluid paths and an analyte sensor adapted to detect a concentration of analyte in the sensing fluid within the sensing zone.

12. The analyte monitor of claim 10 wherein the agent comprises a concentration of citrate in a range from 1.0 mM to 250 mM.

13. The analyte monitor of claim 10 wherein the sensing fluid comprises a phosphate buffered saline solution.

14. The analyte monitor of claim 10 wherein the analyte comprises glucose.

15. The analyte monitor of claim 10 wherein the analyte is other than glucose for example cholesterol, electrolytes or proteins.

16. The analyte monitor of claim 10 wherein the fluid paths each comprise a tissue piercing element.

17. The analyte monitor of claim 10 wherein the fluid paths do not comprise a tissue piercing element.

11. An analyte monitor comprising:

a plurality of fluid paths via micropores through a stratum corneum layer of an area of the individual'"'"'s skin, said fluid paths are in communication with interstitial fluid of the individual, a proximal end in fluid communication with a sensing zone located outside of the patient'"'"'s body; and

where the sensing zone comprises a flexible sensor laminated to a buffered gel allowing at least one analyte to passively diffuse from the patient'"'"'s interstitial fluid through the fluid paths and into the sensing zone wherein the sensing gel formulation comprises a chelating agent adapted to keep the micropores, created by the tissue piercing elements, open for extended period to maintain a constant analyte flux through the fluid paths and to mitigate a decrease over time of the analyte flux through the fluid paths and an analyte sensor adapted to detect a concentration of analyte in the sensing fluid within the sensing zone.